<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511524</url>
  </required_header>
  <id_info>
    <org_study_id>CBA103679</org_study_id>
    <nct_id>NCT00511524</nct_id>
  </id_info>
  <brief_title>An Imaging Study to Investigate the Distribution of GW842166X in the Brain.</brief_title>
  <official_title>An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [11C]GW842166 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GW842166X is being developed for the treatment and management of inflammatory pain. GW842166X
      is a CB2 receptor agonist and the mechanism is not fully understood, although it is thought
      that for the anti-inflammatory action the drug is required to cross inot the brain from the
      blood. This study aims to look at if the drug crosses into the brain once given orally using
      an imaging technique called positron emission tomography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2007</start_date>
  <completion_date type="Actual">July 4, 2007</completion_date>
  <primary_completion_date type="Actual">July 4, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate at which the drug crosses from plasma to brain (ki)using images from the scan</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of drug</measure>
    <time_frame>after taking the drug pre-dose, 2hr, 4hr, 6hr, 10hr, 24hr, follow-up.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pain, Inflammatory</condition>
  <arm_group>
    <arm_group_label>Subjects receiving GW842166</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive [carbonyl-^11C]GW842166.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW842166X</intervention_name>
    <description>GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.</description>
    <arm_group_label>Subjects receiving GW842166</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[carbonyl-^11C]GW842166</intervention_name>
    <description>[carbonyl-^11C]GW842166 will b available as Intravenous solution.</description>
    <arm_group_label>Subjects receiving GW842166</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 50 to 80yrs inclusive at the screening visit.

          -  subjects with negative HIV and hepatitis B and C test results within 3 months of study
             start.

        Exclusion Criteria:

          -  A negative Allens test on arm to be used for arterial cannulation.

          -  Any contraindications to MRI scanning.

          -  History or presence of hepatic or renal disease.

          -  Previous involvement in PET or radiological investigations.

          -  Family history of cancer.

          -  History of claustrophobia

          -  Presence of a cardiac pacemaker or any other electronic device or ferromagnetic metal
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-753 23</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/CBA103679?search=study&amp;search_terms=CBA103679#rs</url>
    <description>Results for study CBA103679 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2007</study_first_submitted>
  <study_first_submitted_qc>August 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain,</keyword>
  <keyword>inflammation,</keyword>
  <keyword>CB2,</keyword>
  <keyword>PET</keyword>
  <keyword>analgesia,</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

